Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto
AssigneesMetabolex, Inc., DiaTex, Inc.
InventorsEdward D. Daugs, Eric J. Hagen, Jason A. Hanko, David H. Louks
Life of this patent
Estimating the term…
Abstract
The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.
Claims4
A compound of (−) halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising a peak at about 10.8°2θ, an infrared spectrum comprising at least one peak selected from about 3322 cm−1 and about 2886 cm−1, and further characterized by at least one of:
- no weight gain at a relative humidity of about 65%;
- and
- a weight gain of about 1.6% at a relative humidity of about 95%.
A compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising peaks at about 10.8°2Θ, about 22.0°2Θ, and 29.3°2Θ, further characterized by at least one of:
- an infrared spectrum comprising peaks at about 3322 cm−1 and about 2886 cm−1, and
- a Raman spectrum comprising peaks at about 3087 cm−1 and about 1663 cm−1,
- and wherein the crystalline solid form A consists of greater than 95% (−)-halofenate and less than 5% of other non-solvent compounds.
A compound of (−) halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising a peak at about 10.8°2θ, an infrared spectrum comprising at least one peak selected from about 3322 cm−1 and about 2886 cm−1 wherein the crystalline solid form A consists of greater than 95% (−)-halofenate and less than 5% of other non-solvent compounds.
Dependencies are inferred from the claim text.